Phase 1b Study of HSP90 Inhibitor, AT13387 in Combination With Paclitaxel in Patients With Advanced, Triple Negative Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 21 Jun 2018
At a glance
- Drugs Onalespib (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 14 May 2018 Planned number of patients changed from 24 to 33.
- 14 May 2018 Planned primary completion date changed from 1 Jan 2018 to 31 Dec 2019.
- 01 Aug 2017 Status changed from suspended to recruiting.